良性前列腺增生手术后尿道狭窄的发生率与管理:来自美国大型数据库的结果
基于PearlDiver™ Mariner数据库2011至2022年数据的回顾性分析,纳入274,808例接受良性前列腺增生手术的患者,术后12个月内尿道狭窄发生率为3.97%,不同术式间发生率存在差异,多因素分析显示PUL、Rezum、Aquablation、PAE和PVP与TURP相比发生尿道狭窄的可能性降低;尿道狭窄病例中76.7%以门诊尿道扩张为主要处理方式,18.95%需手术治疗。
要点
- 274,808例良性前列腺增生手术患者中,术后12个月内尿道狭窄发生率为3.97%。
- TURP术后尿道狭窄发生率4.48%,PUL为1.07%、Rezum为1.05%、PAE为0.65%。
- 尿道狭窄病例中76.7%以门诊尿道扩张为主要处理,18.95%需手术治疗。
核心结论
- 本分析来自当代大型数据集,提示良性前列腺增生手术后尿道狭窄的发生率相对较低(低于5%)且因术式而异。
- 良性前列腺增生手术后约94%的尿道狭窄病例采用尿道扩张和直视下尿道内切开术等微创治疗方式处理。
研究设计与样本
- 回顾性分析,使用PearlDiver™ Mariner数据库2011年至2022年间汇编的去标识患者记录。
- 采用特定国际疾病分类(ICD)和现行操作术语(CPT)编码识别人群特征和结局,纳入良性前列腺增生治疗中最常用的所有手术方式。
- 采用多因素逻辑回归评估与术后尿道狭窄诊断相关的因素。
主要发现
- 274,808例接受良性前列腺增生手术的患者中,10,918例在12个月内发生术后尿道狭窄(3.97%)。
- TURP术后尿道狭窄发生率4.48%,经尿道前列腺切开术(TUIP)3.67%,光选择性前列腺汽化术(PVP)3.92%,HoLEP/ThuLEP 3.85%,开放简单前列腺切除术(SP)3.21%。
- 腹腔镜/机器人辅助简单前列腺切除术(SP)后尿道狭窄发生率1.76%,Aquablation 1.59%,前列腺尿道提升术(PUL)1.07%,Rezum 1.05%,前列腺动脉栓塞术(PAE)0.65%。
- 多因素分析显示,与TURP相比,接受PUL、Rezum、Aquablation、PAE和PVP的患者发生尿道狭窄的可能性降低。
- 尿道狭窄患者中18.95%需要手术治疗,其中直视下尿道内切开术(DVIU)占14.55%,尿道成形术占4.50%;门诊环境下尿道扩张(UD)是大多数病例的主要处理方式(76.7%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: Urethral stricture (US) is a well-known complication after surgical treatment of benign prostatic hyperplasia (BPH). This study aimed to evaluate the contemporary incidence of the US after different types of BPH surgery, to identify associated risk factors and to assess its management. METHODS: A retrospective analysis was conducted using the PearlDiver™ Mariner database, containing de-identified patient records compiled between 2011 and 2022. Specific International Classification of Diseases (ICD) and Current Procedural Terminology (CPT) codes were employed to identify population characteristics and outcomes. All the most employed surgical procedures for BPH treatment were considered. Multivariable logistic regression was employed to evaluate factors associated with diagnosis of post-operative US. RESULTS: Among 274,808 patients who underwent BPH surgery, 10,918 developed post-operative US (3.97%) within 12 months. Higher incidence of US was observed following TURP (4.48%), Transurethral Incision of the Prostate (TUIP) (3.67%), Photoselective Vaporization of the Prostate (PVP) (3.92%), HoLEP/ThuLEP (3.85%), and open Simple Prostatectomy (SP) (3.21%). Lower incidence rates were observed after laparoscopic\robot-assisted SP (1.76%), Aquablation (1.59%), Prostatic Urethral Lift (PUL) (1.07%), Rezum (1.05%), and Prostatic Artery Embolization (PAE) (0.65%). Multivariable analysis showed that patients undergoing PUL, Rezum, Aquablation, PAE, and PVP were associated with a reduced likelihood of developing US compared to TURP. US required surgical treatment in 18.95% of patients, with direct visual internal urethrotomy (DVIU) and urethroplasty performed in 14.55% and 4.50% of cases, respectively. Urethral dilatation (UD) in an outpatient setting was the primary management in most cases (76.7%). CONCLUSIONS: The present analysis from a contemporary large dataset suggests that the incidence of US after BPH surgery is relatively low (<5%) and varies among procedures. Around 94% of US cases following BPH surgery are managed using minimally invasive treatment approaches such as UD and DVIU.
引用
- Licari LC, Bologna E, Manfredi C, et al. Incidence and management of BPH surgery-related urethral stricture: results from a large U.S. database. Prostate Cancer Prostatic Dis. 2024. PMID: 38714780. doi:10.1038/s41391-024-00841-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。